New Delhi: In India, the third wave of Coronavirus, is “inevitable”, and it could hit the country in the next “six to eight” weeks, AIIMS chief Dr Randeep Guleria told a Delhi based news organisation NDTV on Saturday.
As per the report, Guleria said the country’s main challenge is vaccinating a huge population and the increase in dose gaps for Covishield “may not be a bad” approach to provide protection to cover more people.
A new frontier will have to be developed in India’s fight against Covid to further study the mutation of the virus, the report quoted Dr Guleria as saying as he talked about the new Delta-Plus variant, which has evolved from the Delta variant of COVID, triggering fresh concerns about monoclonal antibody treatment.
“As we have started unlocking, there is again a lack of Covid-appropriate behaviour. We don’t seem to have learnt from what happened between the first and the second wave. Again crowds are building up… people are gathering. It will take some time for the number of cases to start rising at the national level.
Third-wave is inevitable and it could hit the country within the next six to eight weeks… maybe a little longer,” Dr Guleria said. “It all depends on how we go ahead in terms of COVID-appropriate behaviour and preventing crowds,” he added.
In India, he said, vaccination is the main challenge. A new wave can usually take up to three months but it can also take much lesser time, depending on various factors.
Apart from COVID-appropriate behaviour, we need to ensure strict surveillance. Last time, we saw a new variant – which came from outside and developed here – led to a huge surge in the number of cases. We know the virus will continue to mutate. Aggressive surveillance in hotspots is required,” the AIIMS chief said, according to the report.
“Mini-lockdown in any part of the country, which witnesses a surge and a rise in positivity rate beyond 5 per cent, will be required. Unless we’re vaccinated, we’re vulnerable in the coming months,” he underlined, stressing that “testing, tracking, and treating” should be the focus in hotspots.
“We have to factor in human behaviour while unlocking, which needs to be done in a graded manner,” Dr Guleria stressed.
On the spread of the Delta variant in the United Kingdom, which is now facing a third wave, Guleria was quoted saying that, “Virus is still mutating, we need to be careful”.
The highly transmissible variant first identified in India is now making up 99 per cent of fresh COVID cases in the UK, news agency PTI reported. The gap between the new waves is shortening and it’s “worrying”, Dr Guleria said.
“During the first wave (in India), the virus was not spreading that rapidly… all that changed during the second wave, and the virus became much more infectious. Now the Delta variant that’s spreading is much more infectious. Faster spread is likely,” NDTV quoted the AIIMS chief as saying.
A debilitating second wave had led to the shortage of hospital beds and medical supplies in various parts of India. SOS messages on social media had caught the world’s attention with many nations coming forward to help. Several states have now eased the restrictions after weeks of strict curbs; however, preparations are on against the third wave.
In Maharashtra, experts have now warned that at its peak, the third wave of the virus could cause 8 lakh active cases in the state, which currently has around 1.4 lakh patients.
“When there is a huge increase in the number of cases, shortage of (hospital) beds follows. The strategy should be multi-pronged – we have to make sure fresh cases don’t rise. Any healthcare system globally will tend to collapse with the unprecedented rise in infections,” Dr Guleria stressed today.
Does India need to rethink its 12-16 week gap decision between two doses of Covishied, a vaccine the country is largely dependent on? “Nothing is written in stone. We will have to look at new strategies. But we need to have strong data to take that decision,” the AIIMS chief said.
The decision should be driven by science and not the shortage of doses, he suggested.
The United Kingdom adopted the one-shot strategy not only for Astrazenaca (which is being used as Covishield in India) but also Pfizer, Dr Guleria pointed out.
“One-shot strategy may not be a bad strategy as it can give protection to larger number of people,” Dr Guleria said.
On the Delta-plus variant, the AIIMS chief, according to the report, explained: “We need an aggressive genome sequencing to see how the virus is behaving. Does the vaccine efficacy come down, does the monoclonal antibody treatment work? To do all of that, we need to have a large or very good network of labs to study the data. I think that’s where to move in the next few weeks. And that’s the new frontier we need to develop if we want to succeed in our fight against Covid.”
Meanwhile, India, in the last 24 hours, recorded 60,753 COVID infections and 1,647 fatalities, according to data released by the Health and Family Welfare Ministry on Saturday.
This is for the second consecutive day in the last two months that the death tally has come down below the 2,000-mark. It is also the 12th consecutive day when India has reported less than one lakh new coronavirus cases.
On June 15, India recorded 60,461 cases, lowest since March 29. The overall tally of COVID cases in the country now stands at 2,98,23,546.
The active cases have come down below 10 lakh. The country has 7,60,019 active cases presently and has witnessed 3,85,137 deaths so far.
According to the Health Ministry, a total of 97,743 people have been discharged in the last 24 hours, taking the total discharge to 2,86,78,390 to date.
The Health Ministry said that a total of 27,23,88,783 people have been vaccinated so far in the country, including 33,00,085 who were administered vaccines in the last 24 hours.
According to the Indian Council of Medical Research, 38,92,07,637 samples have been tested up to June 18 for Covid-19. Of these 19,02,009 samples were tested on Friday.
Free Press Kashmir is now on Telegram. Click here to Join.
FPK Android App for 2G. Click here to Download.
